Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.
GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.
Investors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.